Beyer W E, Noordzij T C, Kramer P, Diderich P P, Op den Hoek C T, Janssen J, Masurel N, Weimar W
WHO Influenza Centre, Department of Virology, Erasmus University Rotterdam; The Netherlands.
Nephron. 1990;54(4):296-301. doi: 10.1159/000185883.
In a double-blind placebo-controlled multicentre study, the effect of the immunomodulator thymopentin (TP5) on the antibody production to trivalent influenza vaccine was tested in 108 patients on chronic intermittent haemodialysis (HD). Antibody production was determined in pre- and postvaccination sera. Compared to a group of 35 young healthy adult control subjects, HD patients showed a clearly impaired seroresponsiveness to all three vaccine components, regardless of treatment with TP5 or placebo. We conclude that TP5 administration is not able to enhance humoral immunity in patients on chronic intermittent HD.
在一项双盲、安慰剂对照的多中心研究中，对108例慢性间歇性血液透析（HD）患者测试了免疫调节剂胸腺五肽（TP5）对三价流感疫苗抗体产生的影响。在接种疫苗前后的血清中测定抗体产生情况。与35名年轻健康成人对照组相比，HD患者对所有三种疫苗成分的血清反应性明显受损，无论接受TP5还是安慰剂治疗。我们得出结论，给予TP5不能增强慢性间歇性HD患者的体液免疫。
